Navigation Links
Breakthrough in treating leukemia, lymphoma with umbilical cord blood stem cells

MAYWOOD, Il. - Donated umbilical cord blood contains stem cells that can save the lives of patients with leukemia, lymphoma and other blood cancers.

Now a study lead by a Loyola University Medical Center oncologist has found that growing cord blood stem cells in a laboratory before transplanting them into patients significantly improves survival.

The cell-expansion technology potentially could boost the number of patients who could benefit from life-saving transplants of stem cells derived from umbilical cord blood, said Patrick Stiff, MD, lead author of the study. Stiff, director of Loyola's Cardinal Bernardin Cancer Center, presented findings at the 2013 annual meeting of the American Society of Hematology.

The ASH meeting is the preeminent annual event for physicians and scientists in hematology. Data from more than 5,300 abstracts were presented, and Stiff's abstract was selected as one of the 2013 meeting's top submissions.

Stem cell transplants can save lives of patients who have no other options. Patients receive high-dose chemotherapy, and in some cases, high-dose radiation as well. The treatment, unfortunately, kills healthy blood cells along with the cancerous cells. To rebuild the stores of healthy cells, the patient subsequently receives a transplant infusion of immature stem cells. Over time, these stem cells develop into new blood cells.

Stem cells are produced in the bone marrow. In many cases, patients receive bone marrow stem cells donated by family members or Good Samaritans who have signed up with a bone marrow registry.

But fewer than 50 percent of eligible patients can find a matching bone marrow donor. In such cases, stem cells derived from umbilical cord blood can be an effective alternative because these cells do not require perfect matches. (The cord blood is donated by parents of newborns, and frozen in a cord blood bank.)

A cord blood donation contains only about one ounce of blood, which usually is enough for only a child or very small adult. Many adults, therefore, receive a double dose of cord blood stem cells donated by two newborns.

The study examined a new technology called StemEx, which grows cord blood stem cells in an outside laboratory. After 21 days, there's a roughly 14-fold increase in the number of stem cells available for transplant.

The study included 25 centers in the United States, Europe and Israel. Researchers used the StemEx technology for cord blood transplants in 101 leukemia and lymphoma patients. These patients were compared with a historical control group of 295 patients who each received a double dose of cord blood stem cells.

After 100 days, the overall survival was significantly higher in the StemEx group ( 84.2 percent) than in the control group (74.6 percent). The StemEx transplants also were quicker to engraft, i.e., develop into a sufficient number of blood cells. In the StemEx group, engraftment of neutrophil blood cells took a median of 21 days, compared with 28 days in the control group. Engraftment of platelets took a median of 54 days in the StremEx group and 105 days in the control group. (Neutrophils are infection-fighting white blood cells; platelets are small blood components that help the clotting process.) The faster neutrophils and platelets are engrafted, the less time patients are vulnerable to infections and bleeding.

The StemEx process has not been approved by the Food and Drug Administration, and is not available to patients except in clinical trials.


Contact: Jim Ritter
Loyola University Health System

Related medicine news :

1. Bascom Palmer Eye Institute announces breakthrough for degenerative vision disorder
2. Scientists make breakthrough in bile duct cancer with discovery of new gene mutations
3. An important breakthrough in immunology by IRCM researchers
4. Ear, Nose & Throat Journal publishes research on breakthrough treatment for tonsil stones
5. Trivedi Beef, LLC Announces Breakthrough Beef Industry Data without the use of Antibiotic Drugs, Hormones or Steroids
6. Breakthrough Brings Transparency to Male/Female Relationships
7. Breakthrough treatment reduces post-surgical scarring for glaucoma patients
8. Research breakthrough could halt melanoma metastasis
9. Breakthrough nanoparticle halts multiple sclerosis
10. Nanomedicine breakthrough could improve chemotherapy for childhood cancer
11. Western University researchers make breakthrough in arthritis research
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
Breaking Medicine Technology: